Wei Ding
Impact in
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research
- Mesenchymal stem cell research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 101
- Chronic Lymphocytic Leukemia Research 101
-
- T-cell and Retrovirus Studies 4
- Co-authors
- Neil E. Kay (76 shared papers)Timothy G. Call (71 shared papers)Tait D. Shanafelt (51 shared papers)Susan L. Slager (59 shared papers)Sameer Ashok Parikh (66 shared papers)Susan Marie Schwager (42 shared papers)Jose Francisco Leis (50 shared papers)Kari G. Rabe (42 shared papers)
- Journals
- Blood (35 papers)American Journal of Hematology (12 papers)British Journal of Haematology (7 papers)Blood Cancer Journal (7 papers)Leukemia (4 papers)
- Partner nations
- United StatesGermanyFinland
In The Last Decade
Wei Ding
113 papers receiving 4k citations
Wei Ding's Hit Papers
Peers
Comparison fields: 5 of 77
- Genetics 3k
- Pathology and Forensic Medicine 331
- Oncology 352
- Hematology 203
- Immunology 161
Countries citing papers authored by Wei Ding
This map shows the geographic impact of Wei Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Ding more than expected).
Fields of papers citing papers by Wei Ding
This network shows the impact of papers produced by Wei Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Ding. The network helps show where Wei Ding may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 116 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL Hit paper breakdown → | 2018 | 751 |
| 2 | Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL Hit paper breakdown → | 2017 | 362 |
| 3 | 2009 | 280 | |
| 4 | 2013 | 196 | |
| 5 | 2016 | 115 | |
| 6 | 2010 | 112 | |
| 7 | 2019 | 109 | |
| 8 | 2008 | 95 | |
| 9 | 2015 | 92 | |
| 10 | 2015 | 88 | |
| 11 | 2015 | 88 | |
| 12 | 2017 | 82 | |
| 13 | 2013 | 78 | |
| 14 | 2009 | 73 | |
| 15 | 2020 | 69 | |
| 16 | 2018 | 67 | |
| 17 | 2009 | 66 | |
| 18 | 2015 | 66 | |
| 19 | 2013 | 64 | |
| 20 | 2019 | 54 |
About Wei Ding
Wei Ding is a scholar working on Genetics, Immunology, Oncology, Hematology and Pathology and Forensic Medicine, having authored 116 papers that have together received 4.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (101 papers), Lymphoma Diagnosis and Treatment (4 papers), CAR-T cell therapy research (4 papers), T-cell and Retrovirus Studies (4 papers), Acute Myeloid Leukemia Research (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), Atrial Fibrillation Management and Outcomes (2 papers) and Genomics and Chromatin Dynamics (2 papers). The work is most often cited by research in Genetics (3k citations), Pathology and Forensic Medicine (331 citations), Oncology (352 citations), Hematology (203 citations) and Immunology (161 citations). Wei Ding has collaborated with scholars based in United States, Germany and Finland. Frequent co-authors include Neil E. Kay, Timothy G. Call, Tait D. Shanafelt, Susan L. Slager, Sameer Ashok Parikh, Susan Marie Schwager, Jose Francisco Leis, Kari G. Rabe, Curtis A. Hanson and Asher Alban Chanan-Khan. Their work appears in journals such as Blood, American Journal of Hematology, British Journal of Haematology, Blood Cancer Journal and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.